On November 29, 2023, Professor Zheng Xiaoqun’s team from the Department of Cardiology at Dalian Municipal Central Hospital completed the first clinical application of the NOVASIGHT? HYBRID SYSTEM coronary imaging system in Northeast China after its launch.
Through the combined application of intravascular ultrasound (IVUS) + optical correlation tomography scanning (OCT) 2-in-1 intravascular imaging technology, it efficiently provides accurate and comprehensive intravascular imaging information. This is also the first clinical application of Grand Pharma’s coronary imaging device NOVASIGHT.
NOVASIGHT? HYBRID SYSTEM, an innovative IVUS+OCT dual-mode imaging system (device + catheter), was approved for marketing by the National Medical Products Administration (NMPA) this year. It is also the only IVUS+OCT dual-mode imaging system that has been approved by the U.S. FDA, and is already in clinical use in the U.S. and Canada.
